About Premature Ejaculation (PE)

About Premature Ejaculation (PE)

Premature ejaculation is a distressing male sexual dysfunction that is much more common than erectile dysfunction (ED). Premature ejaculation can occur at any age, often worsens over time and has a major impact on the quality of life for men and their sexual partners. Ejaculation that occurs before starting sexual intercourse or within two minutes after starting intercourse is considered rapid or ‘premature’ ejaculation and it affects 23% of men worldwide. The true frequency may be even greater because this condition may be embarrassing to discuss. Yet men with recurring premature ejaculation experience significant distress, frustration, anxiety, interpersonal difficulties and avoidance of sexual intimacy. Women often report that their male partners ejaculate faster than they would like and are interested in treatments to help their male partners delay ejaculation.

Previous attempts to treat premature ejaculation with counseling sessions or other behavioral therapies have had only limited success. No drug has been approved in the U.S. for the treatment of premature ejaculation. An antidepressant drug and an anesthetic drug spray that are approved to treat premature ejaculation in some foreign countries have adverse side effects that can limit their use. A safe oral drug that is well-tolerated and effectively delays ejaculation will enhance the quality of life for many men and their sexual partners.

Zertane™ for Premature Ejaculation (PE)

« back to products page

Learn More About:

Premature Ejaculation (PE)

Premature ejaculation is a distressing male sexual dysfunction that is more common than erectile dysfunction (ED) and has a major impact on the quality of life for men and their sexual partners.

Diabetic Retinopathy

A complication of diabetes mellitus that damages the retina in the eyes and leads to blindness

Diabetic Nephropathy

A progressive complication of diabetes mellitus that leads to end-stage renal disease (ESRD) requiring kidney transplantation or chronic dialysis

AMPE Stock Quote - delayed
Last Change
AMPE 2.67 Down 0.14 (4.98%)

Ampio News

05/14/2012 | Press Release

Ampio Pharmaceuticals Schedules 2012 Update Webcast

05/11/2012 | Press Release

Ampio Pharmaceuticals Reports Pre-IND Meeting With the FDA to Obtain Clinical Path Guidance for Ampion™ for the Treatment of Chronic Pain of Osteoarthritis of the Knee and Schedules May 16th Webcast to Update Shareholders

04/30/2012 | Press Release

Ampio Pharmaceuticals announces extended analysis of Ampion™ In the Knee (AIK) Study shows pain relief of osteoarthritis, 84 days after a single injection into the knee, is statistically significant

» See all Ampio news